These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 14768401)

  • 1. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
    Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Sledge GW
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
    Rau KM; Li SH; Chen SM; Tang Y; Huang CH; Wu SC; Chen YY
    Jpn J Clin Oncol; 2011 Apr; 41(4):455-61. PubMed ID: 21193489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
    Delfino C; Caccia G; Gonzáles LR; Mickiewicz E; Rodger J; Balbiani L; Morales DF; Comba AZ; Brosio C
    Oncology; 2004; 66(1):18-23. PubMed ID: 15031594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and paclitaxel in metastatic breast cancer: a review.
    Colomer R
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):8-12. PubMed ID: 15685819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
    Fleming DR; Glisson SD; Bhupalam L; Michelson GD; Goldsmith GH; LaRocca RV
    Am J Clin Oncol; 2000 Aug; 23(4):349-52. PubMed ID: 10955861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
    Zielinski CC
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
    Vici P; Capomolla E; Foggi P; Carpano S; Conti F; Paoletti G; Cauchi C; Giacinti L; Leonetti C; Giannarelli D; Lopez M
    J Exp Clin Cancer Res; 2006 Mar; 25(1):39-44. PubMed ID: 16761616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
    Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
    BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.